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ABSTRACT
Objective: To investigate the relationship between brain microbleeds (MBs) and the rate of cogni-
tive decline in Alzheimer disease (AD).
Methods: In this cohort study, we studied 221 patients with AD with available baseline MRI scans
(1.0 or 1.5 T) and at least 2Mini-Mental State Examinations (MMSE) scores obtainedmore than 1
year apart from our memory clinic. Mean SD follow-up time was 3 1 years, and patients had a
median of 4 MMSE scores (range 2–17). We used linear mixed models with sex and age as cova-
riates to investigate whether MBs influenced the rate of cognitive decline.
Results: Mean age was 68  9 years, 109 (49%) patients were female, and the baseline MMSE
score was 22  4. There were 39 patients (18%) with MBs (median 2, range 1–27) and 182
without. Linear mixed models showed that overall patients declined 2 MMSE points per year. We
found no association of the presence of MBs with baseline MMSE or change in MMSE. Adjust-
ment for atrophy, white matter hyperintensities, lacunes, and vascular risk factors did not change
the results nor did stratification for MB location, APOE 4 carriership, or age at onset (65 years
vs65 years). Repeating the analyses with number of MBs as predictor rendered similar results.
Conclusion: MBs did not influence the rate of cognitive decline in patients with AD. The formerly
reported increased risk ofmortality in patientswithMBsseemsnot tobeattributable to a steeper rate
of decline per se but might be due to vascular events, including (hemorrhagic) stroke. Neurology®
2012;79:763–769
GLOSSARY
A 1–42  Amyloid- 1–42; AD  Alzheimer disease; ARIA  amyloid-related imaging abnormalities; CAA  cerebral amy-
loid angiopathy; CTA  cortical temporal lobe; GRE  gradient echo; MB  microbleed; MCI  mild cognitive impairment;
MMSE  Mini-Mental State Examination; MTA  medial temporal lobe atrophy; Ptau-181  tau phosphorylated at
threonine-181.
Microbleeds (MBs) are small rounded regions of hypointensities on gradient echo (GRE)
T2*-weighted MRI scans, which frequently occur in patients with Alzheimer disease (AD).1–4
Histologically, MBs represent hemosiderin, probably from leakage through cerebral small ves-
sels, contained within surrounding macrophages in the brain parenchyma.5 In the setting of
AD, lobar MBs in particular are believed to arise from leakage from fragile amyloid-laden vessel
walls, defined as cerebral amyloid angiopathy (CAA).6 The relationship between MBs or CAA
and cognition in AD is unclear. Cross-sectionally, some studies found that AD patients with
CAA or MBs are more severely cognitively impaired,7,8 whereas others found no such relation-
ship.2,3,6,9 Several cross-sectional studies have reported a relationship between MBs and cogni-
tion in elderly individuals with or without increased vascular risk and in patients with small and
large vessel disease.1,10–16 Previous studies have shown that patients with MBs have a higher risk of
mortality.17,18 It is not known, however, whether patients with AD with MBs are prone to a more
rapid rate of cognitive decline. In the present cohort study, we hypothesized that the presence of
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MBs reflects a heavier burden of pathology in
AD, resulting in a steeper rate of cognitive de-
cline. The aim of this study was to assess the
predictive value of baseline MBs on cognitive
decline over time in patients with AD.
METHODS Patients, design, and setting. In this cohort
study, we included consecutive patients with AD who presented
between 2000 and 2008 at the outpatient memory clinic of the
Alzheimer Center of the VU University Medical Center, with
baseline MRI with GRE sequence on 1.0- or 1.5-T machine and
a minimum duration of follow-up of 1 year. At baseline, all
patients underwent a standardized dementia assessment includ-
ing medical history, informant-based history, physical and
neurologic examination, laboratory tests, neuropsychological
testing, EEG, and MRI of the brain. Furthermore, we obtained
information on smoking habits, current use of Alzheimer medi-
cation or antithrombotic drugs and medical history. Hyperten-
sion, diabetes mellitus, hypercholesterolemia, and myocardial
infarction were defined based on self-reported medical history
and medication use. Diagnoses of probable AD were made in a
multidisciplinary consensus meeting according to the National
Institute of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related Disorders Asso-
ciation diagnostic criteria.19 None of the patients had symptom-
atic brain hemorrhage. The level of education was classified
using the 7-point rating scale of Verhage ranging from 1 (low,
elementary school not completed) to 7 (high, university). Au-
topsy was available for 5 patients (2 with MBs and 3 without
MBs). The diagnosis of AD was confirmed in all patients. In 1
patient (no MBs), significant coexistent vascular pathology was
mentioned.
We followed patients clinically, with (semi-)annual assess-
ment of their general level of cognitive functioning. The out-
come measure was the Mini-Mental State Examination (MMSE)
score.20 To be included in this study, patients had to have a
minimum of 2 MMSE scores at least 1 year apart. The resulting
dataset included 1,021 MMSE scores from 221 patients.
Follow-up time varied between 1 and 7 years (mean SD 3 1
years), and patients had a median of 4 MMSE scores (range
2–17) (table).
Standard protocol approvals, registrations, and patient
consents. The study was approved by the local medical ethics
committee. All patients gave written informed consent for their
clinical data to be used for research purposes.
MRI. Baseline MRI was performed on a 1.0-Tesla machine
(n  179; Magnetom Impact Expert; Siemens AG, Erlangen,
Germany) or a 1.5-T machine (n  42; Sonata Syngo; Siemens
AG). The scan protocol included T1-weighted, T2-weighted,
fluid-attenuated inversion recovery (FLAIR), and GRE images
and has been described previously.1,21 Scan parameters for the
axial GRE images used for MB detection were as follows: impact,
19 slices; field of view, 250 mm; matrix, 256  256; slice thick-
ness, 5 mm; interslice gap, 1 mm; repetition time, 800 msec;
echo time, 22–25 msec; flip angle, 20°. Scan parameters for So-
nata were as follows: 21 slices; field of view, 250 mm; slice thick-
ness, 5 mm; interslice gap, 1.5 mm; repetition time, 415 msec;
echo time; 25 msec; flip angle, 15°.
MRI scan rating was performed blinded to clinical data.
MBs were defined as rounded hypointense homogeneous foci
measuring up to 10 mm in the brain parenchyma on GRE im-
ages. Lesions in sulci possibly representing flow voids from pial
vessels and symmetric lesions in the basal ganglia, supposedly
representing iron or calcium deposits, were not taken into ac-
count. Hypointensities inside infarcts were not counted as MBs
but were regarded as being probable hemorrhagic transforma-
tions. Cavernous angiomas were not taken into account. We
counted MBs in 4 lobar regions (frontal, parietal, temporal, and
occipital) and in 2 nonlobar regions (basal ganglia including
thalamus and infratentorial). The main determinant was the
presence of at least one MB. In additional analyses, the number
of MBs and MB by location were used as determinants.
We performed visual rating of medial temporal lobe atrophy
(MTA) on coronal T1-weighted images according to the 5-point
(0–4) Scheltens scale.22 Global cortical atrophy (GCA) (range
0–3)23 and white matter hyperintensity (WMH) severity (Faze-
kas, range 0–3)24 were rated visually on axial FLAIR images; the
highest scores represent maximal pathology. We counted lacunar
Table Baseline demographic and clinical characteristics
Nomicrobleeds >1microbleeds
No. patients 182 39
Female sex, n (%) 94 (52) 15 (39)
Age, y, mean (SD) 67 (9) 71 (8)a
Education, median (range)b,g 5 (2–7) 5 (2–7)
APOE 4 carriers, n (%)c 111 (71) 20 (69)
MMSE score at baseline, mean (SD) 22 (4) 22 (4)
Follow-up time, y, mean (SD) 3 (1) 3 (1)
No. of MMSE scores, median (range) 4 (2–17) 4 (2–10)
Mortality, n (%) 24 (13) 8 (21)
Smoking, n (%)d 26 (16) 3 (8)
Hypertension, n (%)b 48 (27) 20 (51)a
Diabetes mellitus, n (%)b 12 (7) 3 (8)
Hypercholesterolemia, n (%)b 28 (16) 9 (23)
Myocardial infarction, n (%)b 6 (3) 3 (8)
Use of antithrombotic drugs, n (%)b 32 (18) 13 (33)a
Use of Alzheimer medication, n (%)b 13 (7) 2 (5)
CSF amyloid- 1–42, pg/mLe,f 459 (166) 406 (153)a
Total tau, pg/mLe,f 639 (399) 739 (497)
Tau phosphorylized at threonine 181, pg/mLe,f 87 (34) 94 (44)
Microbleeds, median (range) 2 (1–27)a
MTA, mean (SD)f 1.4 (0.9) 1.9 (1.0)a
GCA, mean (SD)f 1 (1) 1 (1)
WMHs, mean (SD)e 0.8 (0.8) 1.5 (1.0)a
Lacunes, mean (SD)d 0 (0) 0 (1)
Abbreviations: GCA  global cortical atrophy; MMSE  Mini-Mental State Examination;
MTAmedial temporal lobe atrophy; ptau tau phosphorylized at threonine 181; WMH
white matter hyperintensity.
a p 0.05.
b Data available for 219 patients.
c Data available for 186 patients.
d Data available for 196 patients.
e Data available for 158 patients.
f Analyses were performed with nonparametric Mann-Whitney U tests.
g Education was rated using Verhage code, ranging from 1 (elementary school not finished)
to 7 (university).
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infarcts, defined as well-demarcated lesions from 3 to 15 mm,
with a CSF-like signal on all sequences.
APOE and CSF biomarkers. DNA was isolated from 10 mL
of EDTA blood. The APOE genotype was determined with the
Light Cycler APOE mutation detection method (Roche Diag-
nostics GmbH, Mannheim, Germany). The APOE genotype
was available for 186 patients. CSF biomarkers were assessed as
markers of Alzheimer neuropathology. CSF was obtained by a
lumbar puncture. Amyloid- 1–42 (A42), total tau, and tau
phosphorylated at threonine-181 (Ptau-181) were measured by
sandwich ELISA (Innotest -amyloid(1–42), Innotest hTau Ag,
and Innotest Phospho tau(181P); Innogenetics, Gent, Belgium).25
CSF was available for 158 patients.
Statistical analysis. We used SPSS 15.0 to perform statistical
analyses. Baseline differences between groups were studied using
Student t test, Mann-Whitney U test, or 2 test where applica-
ble. We used linear mixed models to assess associations between
the presence of MBs and the rate of cognitive decline as mea-
sured by MMSE. This approach has increased statistical power
because it accounts for within-person correlations over time, al-
lows different numbers of assessments, and accounts for varying
time intervals between assessments. A random intercept and a
random slope with time (in years) were assumed, i.e., baseline
MMSE (main effect of MBs) and change in MMSE over time
(interaction effect of MBs  time) were allowed to vary between
patients. The first model included terms for the presence of
MBs, time, and the interaction between presence of MBs and
time with sex and age as covariates and MMSE score as the
dependent variable. Secondly, we used a model with additional
adjustment forMTA,GCA,WMHs, and the presence of lacunes. A
third model also adjusted for the following potential confounders:
smoking, hypertension, diabetes, hypercholesterolemia, myocardial
infarction, and use of antithrombotic drugs or Alzheimer medica-
tion. Furthermore, we repeated the analyses after stratification
according to age at onset (65 years vs 65 years) and accord-
ing to APOE- 4 carriership (noncarriers vs carriers). The same
models were run with a term for the number instead of the
presence of MBs. Finally, we ran the models again to assess the
influence of the location of MBs on the rate of MMSE score
change over time in 2 ways: first with a categorical variable based
on the presumed underlying etiology, defined as 1) no MBs, 2)
strictly nonlobar MBs, 3) strictly lobar MBs, and 4) both lobar
and nonlobar MBs and second with a categorical variable based
on laterality defined as 1) no MBs, 2) left-sided MBs, 3) right-
sided MBs, and 4) bilateral MBs.
RESULTS Demographic and clinical characteristics
of the study sample are presented in the table. Of the
patients, 18% had one or more MBs, and 82% had
no MBs. Patients with MBs were older than patients
without MBs. Groups did not differ in sex, educa-
tion, APOE 4 carriership, follow-up time, or num-
ber of follow-ups. Patients with MBs more often died
within the study period, although this difference did
not reach significance. Patients with MBs more often
had a history of hypertension, and they more often
used antithrombotic drugs, but there were no differ-
ences in other vascular risk factors. Furthermore, pa-
tients with MBs had lower CSF levels of A42, but
there were no differences in tau or Ptau-181. Relative
to normal values, both groups showed decreased CSF
levels of A42 and increased CSF levels of total tau
and Ptau-181 (normal values: A42 550, total tau
375, and Ptau-18152).25 Patients with MBs had
more MTA and WMHs than patients without MBs.
We found no differences between groups for GCA or
number of lacunes.
Linear mixed models with random intercept and
slope showed that across groups, patients declined 2
MMSE score points per year ( [SE]  2.10
[0.31], p  0.00). No association of MB presence
with baseline MMSE ( [SE]  0.26 [0.72], p 
0.72) or rate of cognitive decline ( [SE]  0.01
[0.34], p  0.97) was found (figure 1). Adjustment
for MTA, GCA, WMHs, and number of lacunes did
not change the results (baselineMMSE score:  [SE]
0.34 [0.76], p  0.65); rate of decline:  [SE] 
0.09 ([0.34], p  0.79), nor did further adjustment
for smoking, hypertension, diabetes, hypercholester-
olemia, myocardial infarction, or use of antithrom-
botic drugs or Alzheimer medication. In addition,
stratification according to age at onset (figure 2) and
APOE 4 carriership (figure 3) did not reveal any
associations between MBs and cognition. We re-
peated all analyses with MBs as a continuous measure
to study the associations with the number, rather
than the presence, of MBs, which did not reveal any
associations with baseline MMSE score or rate of
cognitive decline either. Furthermore, restricting the
Figure 1 Number of microbleeds (MBs) byMini-Mental State Examination
(MMSE) score change per annum
MMSE score change per annum was calculated as last MMSE score minus first MMSE
score, divided by follow-up time in years. Note that for the statistical analysis linear mixed
modelswere used, which showed no association betweenMBs and rate of cognitive decline.
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sample to patients with MBs only showed no associ-
ations of number of MBs with baseline MMSE (
[SE]  0.15 [0.13], p  0.23) or rate of cognitive
decline ( [SE] 0.00 [0.05], p 0.98). When the
location of the MBs (no MBs, strictly nonlobar MBs,
strictly lobar MBs, or both lobar and nonlobar MBs)
was taken into account, we observed no association
of location of MBs with baseline MMSE or rate of
cognitive decline (all p values0.05) (figure 4). Sim-
ilarly, location of MBs in terms of laterality (no MBs,
left-sided MBs, right-sided MBs, or bilateral MBs)
did not reveal any associations (data not shown).
DISCUSSION The main finding of this longitudi-
nal study is that the presence and number of MBs are
not associated with rate of cognitive decline in AD.
Neither stratification for age at onset or APOE geno-
type, nor taking into account MB location (deep vs
lobar or left hemisphere vs right hemisphere), nor
restricting the analysis to patients with MBs only re-
vealed any significant relation between MBs and rate
of cognitive decline in this clinical sample of patients
with AD.
There are 2 former longitudinal studies that have
looked into the relationship between MBs and rate of
cognitive decline in mild cognitive impairment
(MCI) and are in line with our findings. One study
found no difference in MBs between patients with
stable and progressive MCI after 1 year.26 The other
study found that the presence of MBs predicts con-
version from MCI to dementia, but the significance
of this effect was lost after adjustment for age.27
Previous studies have suggested that the presence
of one or a few MBs does no real harm but having
multiple MBs is indicative of a more malignant out-
come. Despite a modestly, although nonsignifi-
cantly, increased mortality rate, we were not able to
demonstrate an association between the presence or
number of MBs and rate of cognitive decline. In AD,
it seems that downstream phenomena such as loss of
synapses and neurodegeneration are largely responsi-
ble for cognitive decline. Our results suggest that
MBs do not affect these downstream pathologic Alz-
heimer processes. Two previous studies showed that
patients with multiple MBs have a higher risk of
mortality.17,18 Our current results support the notion
that the increased risk of mortality in patients with
AD with MBs is not related to the Alzheimer process
itself, but rather to vascular events, including (hem-
orrhagic) stroke.
Variability in rate of decline on MMSE in our
sample of patients with AD was large. The determi-
nants of the rate of decline in AD are largely un-
known, because we are presently unable to predict
which patients will show faster progression than oth-
ers. The current study shows that MBs are not an
important determinant of rate of decline in AD. We
cannot exclude the possibility that MBs have a subtle
effect on rate of cognitive decline; however, in the
context of AD, the clinical significance of such a
subtle effect would be limited. Still, MBs may in-
fluence change in cognition in other populations,
such as populations without dementia. Cross-
sectionally, several studies have reported a relationship
between MBs and cognition in elderly individuals
with or without increased vascular risk10–12,14 and in
patients with small- and large-vessel disease.13,15
Whether MBs also predict change in cognitive per-
formance over time in these populations remains to
be determined.
We took into account location of MBs in a num-
ber of analyses, but we found no relationship be-
tween MBs in a specific location (be it lobar vs
nonlobar or left vs right hemisphere) and rate of cog-
nitive decline. It is still conceivable that the localiza-
tion of MBs could be relevant, but that such an effect
is not reflected in the overall MMSE score. Cross-
sectional studies have suggested that MBs are largely
related to tests of mental speed and executive func-
tioning.10,13–15 Whether or not the exact location of
MBs is relevant in terms of reflecting focal damage
Figure 2 AnnualMini-Mental StateExamination (MMSE) score for patientswith
andwithoutmicrobleeds (MBs), stratified according to age at onset
Annual MMSE score change was calculated as last MMSE score minus first MMSE score,
divided by follow-up time in years. Note that for the statistical analysis linear mixed models
were used, which showed no association between MBs and rate of cognitive decline for
either patients with early or late disease onset (65 years or65 years).
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remains to be demonstrated, however. Alternatively
and perhaps more likely is the view that MBs are a tip
of the iceberg phenomenon, reflecting widespread
underlying vasculopathy.
The current study was designed to relate baseline
MRI scans to changes in cognitive functioning. Re-
peated MRI scans would have allowed us to relate the
incidence of new MBs to rate of cognitive decline,
but this was beyond the scope of the current study.
In a former study, we have shown that incident MBs
occurred in 12% of patients over a 2-year period and
were not related to change in cognition.28 Similarly,
others have shown that the occurrence of new MBs
did not predict clinical decline in patients with intra-
cerebral hemorrhage.16
Among the strengths of the current study is the
large sample size of patients who were all screened
using the same, careful diagnostic workup. MRI pro-
tocols were kept constant over the whole inclusion
period. Although misdiagnoses cannot be completely
ruled out, all diagnoses were made according to clin-
ical criteria and patients were followed clinically.
Moreover, in the majority of patients, CSF biomark-
ers were available to substantiate the clinical diagno-
sis. Another strength is the use of linear mixed
models for statistical analyses. These models take
into account all available data points, allowing pa-
tients to have variable numbers of follow-up mea-
surements. In this way, patients with only 2 available
MMSE scores could also be included in the study,
because the statistical model appropriately takes into
account the fact that the estimate of cognitive decline
is less precise in these patients. A potential limitation
is the relatively few patients with AD with MBs, be-
cause despite the large sample size of 221 patients
with clinical follow-up, only 39 had MBs. Still, this
number is in agreement with the previously reported
prevalence of MBs in AD and the large group of
patients without any MBs adds power to the statisti-
cal analyses. A second limitation is that although in-
formation on the use of Alzheimer medication and
other types of medication at baseline was available,
use of medication in the course of the disease was not
recorded. Nonetheless, although the use of cholines-
terase inhibitors and memantine may have influ-
enced the rate of cognitive decline, we do not suspect
that this effect would be different for patients with
MBs than for those without MBs. Third, our out-
come measure was the MMSE score, a crude measure
of cognitive decline, which does not capture all as-
pects of disease severity. Still, the MMSE is a gener-
ally accepted and widely used test for the evaluation
of cognition in elderly patients. A future study
should investigate the impact of MBs on the decline
of specific cognitive domains and on the relation-
ships between MBs and neuropsychiatry symptoms
in populations without dementia also, in which the
subtle effects of MBs may still be discerned.
Figure 3 Annual Mini-Mental State Examination (MMSE) score change for
patients with and without microbleeds (MBs), stratified according
to APOE 4 genotype
Annual MMSE score change was calculated as last MMSE score minus first MMSE score,
divided by follow-up time in years. Note that for the statistical analysis linear mixed models
were used, which showed no association between MBs and rate of cognitive decline for
either APOE 4 carriers or noncarriers.
Figure 4 Annual Mini-Mental State Examination (MMSE) score change
according to the presence and location of microbleeds (MBs)
Linear mixed models showed no association between the location of MBs and the rate of
cognitive decline.
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Recently, the interest in the clinical consequence
of MBs has risen, because amyloid-related imaging
abnormalities (ARIA) including cerebral MBs have
occurred in patients participating in clinical trials
with therapeutic agents to lower the amyloid- bur-
den in AD.29 In this context, our finding of a lack of
association between MBs and the rate of cognitive
decline may be of importance. If the rate of cognitive
decline, often a primary outcome measure in clinical
trials, is not influenced by the presence and number
of MBs, excluding patients with MBs may not be
necessary. However, it should be noted that the prog-
nosis of ARIA-hemosiderin deposition may be differ-
ent from that of spontaneously occurring MBs.
Therefore, further research is needed regarding the
risk of accelerated cognitive decline in patients with
ARIA-hemosiderin deposition.
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Registration Now Open for 2012 AAN Fall
Conference in Las Vegas
Registration is now open for the 2012 AAN Fall Conference set for October 26–28 at the Encore at
Wynn, Las Vegas. The Fall Conference offers a unique opportunity to stay informed about the latest
developments in key areas of clinical neurology and practice issues—while earning up to 17.5 hours
of CME credits.
Early registration discounts end October 1. The hotel reservation deadline is September 24. Regis-
tering for the full three-part Neurology Update or Practice Management Program track saves you an
extra 10%.
Seating is limited for this highly popular education program.
Visit www.aan.com/view/fallconf today!
Be a Leader
NEW! 2012-2013 AAN Emerging Leaders Forum
The American Academy of Neurology is seeking up to 10 highly motivated members 45 years of
age or younger, or no more than 13 years out of training, for a competitive program designed to
develop leadership skills with the world’s largest professional association of neurologists. The pro-
gram seeks to:
• Identify, orient, and cultivate future leaders from the young AAN membership
• Develop and implement a formal AAN mentoring program between participants and established
AAN leaders
• Enhance skills of those participants who have already assumed or are about to assume leadership
roles with the AAN; successful participants may be offered an opportunity to serve on an AAN
committee, subcommittee, or presidential task force
Application Deadline: September 1, 2012
For details and to apply, visit www.aan.com/view/Leadership
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